Clinical trials: Endocrine, Nutritional, Metabolic and Immunity Disorders
Type 1 Diabetes Mellitus
Mesenchymal Stem Cells in Patients With Type 1 Diabetes Mellitus
In this prospective, dual-center, open trial, patients with recent onset type 1 diabetes will receive one dose of allogenic Adipose tissue-derived stromal/stem cells (1x106 cells/kg) and oral cholecalciferol 2000UI/day for 24…
- Trial name
- NCT03920397
- Testing
- Infusion of adipose tissue-derived stem/stromal cells and oral Cholecalciferol supplementation
- Where
- Brazil
- Volunteers
- 30 people
- Sponsor
- Universidade Federal do Rio de Janeiro
Type 1 Diabetes
Impact of Introducing Basaglar Insulin to the Treatment Regimen of Youth With Diabetes in Pakistan
This study aimed to determine the effect of introducing Basaglar and insulin pen injection devices on clinical and quality of life (QOL) parameters in children and young adults with type 1 diabetes in Pakistan
- Trial name
- NCT06717191
- Testing
- biosimilar insulin glargine
- Where
- Pakistan
- Volunteers
- 296 people
- Sponsor
- Life for a Child Program, Diabetes Australia
Hypoglycemia Unawareness
Carvedilol in Treating Hypoglycemia Unawareness
Type 1 diabetes mellitus (T1DM) can lead to cardiovascular, renal and neurological complications if left poorly-controlled over prolonged periods of time.
- Trial name
- NCT03538015
- Testing
- Carvedilol 3.125 mg, Carvedilol 2.5 mg
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Owen Chan, PhD
Type 1 Diabetes Mellitus
The Effect of Insulin Glulisine Compared With Insulin Aspart on Breakfast Post Prandial Glucose Levels in Prepubertal Children
To determine whether insulin glulisine decreases the breakfast post prandial glycemic excursion in comparison to insulin aspart.
- Trial name
- NCT00913497
- Testing
- insulin glulisine, insulin aspart
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Corewell Health West
Type 1 Diabetes Mellitus
Continuous Glucose Monitoring to Measure Effect of Glycemic Index
Background: Post-prandial hyperglycemia is common in people with type 1 diabetes. Objective: The aim was to determine the impact of low vs high glycemic index (GI) on post-prandial glycemia for breakfast vs lunch and to quantify…
- Trial name
- NCT01145547
- Testing
- Dexcom Seven® Plus Continuous Glucose Monitoring sensor
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Legacy Health System
Diabetes Mellitus, Type 1, Diabetes Mellitus
Azithromycin Insulin Diet Intervention Trial in Type 1 Diabetes
Increasing evidences suggest that infections are important etiological factors for the development of Type 1 Diabetes (T1D). The overall hypothesis of the study is that the treatment of children, during the first year after…
- Conditions
- Diabetes Mellitus, Type 1, Diabetes Mellitus, Metabolic Disease, Glucose Metabolism Disorders
- Trial name
- AIDIT (NCT03682640)
- Testing
- Azithromycin Monohydrate, Insulin Lispro, Dietician support
- Where
- Sweden
- Volunteers
- 60 people
- Sponsor
- Uppsala University
Diabetes Mellitus, Type 1
Empagliflozin add-on to Insulin in Type 1 Diabetes Mellitus Over 28 Days
Placebo-controlled, double blind (triple-dummy technique), randomised parallel design comparison of three oral doses (2.5 mg, 10 mg, and 25 mg) of empagliflozin in patients with T1DM as adjunctive therapy to insulin over 28 days.
- Trial name
- NCT01969747
- Testing
- Empagliflozin medium, Empagliflozin low
- Where
- 2 sites in Austria, Germany
- Volunteers
- 75 people
- Sponsor
- Boehringer Ingelheim
Kidney Transplant, Familial Hypercholesterolaemia
Cardiovascular Risk in Children With Chronic Conditions Study
Children living with chronic health conditions face a higher risk of developing cardiovascular diseases than their peers, largely due to the accelerated aging of the heart and blood vessels.
- Conditions
- Kidney Transplant, Familial Hypercholesterolaemia, Type 1 Diabetes Mellitus (T1DM), Type 2 Diabetes Mellitus (T2DM)
- Trial name
- CR3C (NCT07086989)
- Where
- 3 sites in Hungary
- Volunteers
- 300 people
- Sponsor
- Semmelweis University
Type 1 Diabetes Mellitus
A Trial Investigating the Continuous Subcutaneous Insulin Infusion of a Liquid Formulation of BioChaperone Insulin Lispro in Comparison to Humalog®
This study is constituted of 2 parts: Part A: A total of 36 patients will be enrolled in part A. Each eligible subject will participate in two 14-day treatment periods with Continuous Subcutaneous Insulin Infusion (CSII) of…
- Trial name
- NCT02562313
- Testing
- BioChaperone insulin lispro, Humalog®
- Where
- Germany
- Volunteers
- 80 people
- Sponsor
- Adocia
Type 1 Diabetes
Sensor-Augmented Insulin Delivery: Insulin Plus Glucagon Versus Insulin Alone
This study aims to test an insulin and glucagon delivery algorithm designed to be used in conjunction with a continuous glucose monitoring system.
- Trial name
- NCT00797823
- Testing
- Insulin, Asp(B28)-, Glucagon
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Legacy Health System
Type 1 Diabetes Mellitus
Pramlintide Combined With Model Predictive Control Algorithm
This is a scientific research study that will look at how a "closed-loop" system and the drug Pramlintide may work together to improve blood sugar control in people with type 1 diabetes mellitus.
- Trial name
- ALM002 (NCT01434862)
- Testing
- Closed loop with pramlintide, Closed loop without pramlintide, Open loop with pramlintide
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Virginia
Diabetes, HIV Infections
The Study of HIV Protease Inhibitors and Their Effects on Glucose Metabolism
The purpose of this study is to determine the mechanisms by which HIV protease inhibitors contribute to the development of diabetes in HIV-infected patients.
- Conditions
- Diabetes, HIV Infections, Insulin Resistance
- Trial name
- NCT00259727
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- US Department of Veterans Affairs
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
A Research Study to Look at How Faster Aspart Works in Chinese People With Type 1 Diabetes or Type 2 Diabetes
This study looks at how faster aspart reaches and stays in the blood after injection in Chinese people with type 1 diabetes or type 2 diabetes, compared to the reference product called NovoRapid®.
- Trial name
- NCT04698018
- Testing
- Faster Aspart, Novo Rapid
- Where
- 3 sites in Germany, Hong Kong
- Volunteers
- 23 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
An Observational Study in Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes Mellitus
This trial is conducted in Europe. The aim of this trial is to investigate efficacy and safety of NovoMix® 30 (biphasic insulin aspart 30) or Levemir® (insulin detemir) in subjects with type 1 or 2 diabetes mellitus.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT01542424
- Testing
- biphasic insulin aspart 30, insulin detemir
- Where
- North Macedonia
- Volunteers
- 1,889 people
- Sponsor
- Novo Nordisk A/S
Autoantibody Positive, Non-diabetic Relatives at Risk for Type 1 Diabetes
Teplizumab for Prevention of Type 1 Diabetes In Relatives "At-Risk"
The study will determine whether the anti-CD3 monoclonal antibody, teplizumab, can help to prevent or delay the onset of type 1 diabetes (T1D) in relatives determined to be at very high risk for developing the disease.
- Conditions
- Autoantibody Positive, Non-diabetic Relatives at Risk for Type 1 Diabetes, High Risk, Impaired Glucose Tolerance
- Trial name
- NCT01030861
- Testing
- Teplizumab
- Where
- 19 sites in United States, Canada and 1 more
- Volunteers
- 76 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type 1 Diabetes Mellitus
Chinese Alliance for Type 1 Diabetes Multi-center Collaborative Research
The China Alliance for Type 1 Diabetes (CAT1D) is committed to exploring and implementing the model of graded diagnosis and treatment of type 1 diabetes and comprehensive management of outpatient service, carrying out a series of…
- Trial name
- NCT04096794
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Second Xiangya Hospital of Central South University
Type 1 Diabetes
The International Diabetes Closed Loop (iDCL) Trial: Protocol 4
The investigators aim to compare the efficacy and safety of an AID system using an adaptive MPC algorithm versus SAP (which may or may not include PLGS; to be referred to as SAP) in people with type 1 diabetes.
- Trial name
- DCLP4 (NCT04436796)
- Testing
- interoperable Artificial Pancreas System (iAPS), Sensor-Augmented Pump (SAP)/Predictive Low Glucose Suspend (PLGS)
- Where
- 5 sites in United States
- Volunteers
- 35 people
- Sponsor
- Sansum Diabetes Research Institute
Type 1 Diabetes
Closed-Loop Glucagon Administration For Hypoglycemia Treatment
This study will test the hypothesis that a wearable automated bionic pancreas system that automatically delivers glucagon only can prevent or treat hypoglycemia vs. usual care for people with type 1 diabetes > 21 years old.
- Trial name
- NCT02181127
- Testing
- Glucagon-only Bionic Pancreas
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Diabetes Mellitus, Type 1
Pre-Approval Access to Golimumab Subcutaneous for the Treatment of Stage 3 Type-1 Diabetes Mellitus in Children and Young Adults
This is a Single Patient Investigational New Drug (IND) to golimumab subcutaneous (SC) for the treatment of recently diagnosed Stage 3 type-1 diabetes mellitus (T1D) in children and young adults.
- Trial name
- NCT03945903
- Testing
- Golimumab
- Where
- United States
- Sponsor
- Janssen Research & Development, LLC
Type 1 Diabetes
Equivalence of A Stable Liquid Glucagon Formulation With Freshly Reconstituted Lyophilized Glucagon
This study will test the hypothesis that micro-doses of Xerisol Glucagon (Xeris Pharmaceuticals) will be non-inferior by pharmacokinetic and pharmacodynamic criteria vs. micro-doses of Glucagon for Injection (Eli Lilly).
- Trial name
- NCT02018627
- Testing
- Xeris glucagon, Lilly glucagon
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Steven J. Russell, MD, PhD
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.